IRF1 and esophageal squamous cell carcinoma: In this study, we demonstrated that Nur77 could inhibit the tumorigenesis and progression of ESCC via the downregulation of IRF1/PD-L1 expression and significantly enhance immunotherapy efficacy in ESCC patients.